Sionna Therapeutics (SION) Capital Expenditures (2024 - 2025)
Quarterly results put Capital Expenditures at $204000.0 for Q4 2025, up 655.56% from a year ago — trailing twelve months through Mar 2026 was $291000.0 (up 157.52% YoY), and the annual figure for FY2025 was $377000.0, up 1296.3%.
Sionna Therapeutics has reported Capital Expenditures over the past 2 years, most recently at $204000.0 for Q4 2025.
- Capital Expenditures reached $204000.0 in Q4 2025 per SION's latest filing, up from $87000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $204000.0 in Q4 2025 and bottomed at $27000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 230.60 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Sionna Therapeutics | 1.87 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 204,000.00 |
| Dec 31, 2025 | 204,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |